Fab four make Babraham Accelerator’s new cohort
Healthcare advances for humans and animals in a range of disease areas are represented in Babraham Research Campus’ third cohort of life science start-ups chosen for the [email protected] 2020/21 programme.
Judges hand-picked four outstanding startups covering the fields of new therapeutics, diagnostics and medical devices, namely:-ArcVax; Cambridge Paediatric HealthTech; ConcR and Stroma Biosciences.
ArcVax has created a new technology platform for low-cost animal vaccines against several bacteria affecting poultry, pigs and ruminants.
Cambridge Paediatric HealthTech is aiming to positively change the development, learning and life chances of children with hearing loss.
ConcR is using custom developed software to combine multiple approaches and data sources into a single holistic approach for modelling tumour progression.
Stroma Biosciences, a University of Cambridge spinout from the Department of Haematology and Cambridge Stem Cell Institute, aims to develop therapeutics specifically targeting stroma-instrinic mechanisms in the heterogeneous microenvironment that are responsible for environment-mediated drug resistance and immune modulation in oncology and autoimmune disorders.
The winners secure five months access to [email protected]’s bio-incubator facilities, including use of communal equipped laboratory space and flexible workspaces.
Each also receives £10K non-dilutive funding; personal mentoring from world class experts in the fields of science and business and access to the Babraham Research Campus’ extensive business and investor networks.
The 2020/21 [email protected] programme will challenge the start-ups thinking through a series of supportive and informative training sessions, workshops and 1-2-1 mentoring.
All facilitated by experts in life science, bio-innovation and business, the sessions are designed to help the start-ups develop every aspect of their venture whilst also affording them the time and specialist space to concentrate on accelerating their science.
[email protected] is supported by a number of strategic partners including; AstraZeneca, Eisai, LifeArc and Mundipharma.
The first day of the new programme began with an introduction from Derek Jones, CEO of Babraham Bioscience Technologies, the organisation which develops and manages the campus.
The cohort were invited to put their questions to a panel of life science investors, entrepreneurs and industry experts – namely Allan Marchington, managing partner of Bridge Valley Ventures; independent consultant Jane Dancer; entrepreneur and Cambridge Angel Andy Richards; Jane Osbourn, CSO Alchemab Therapeutics; Jill Reckless, CEO, RxCelerate; Robert Tansley, partner, Cambridge Innovation Capital; Derek Jones, CEO, BBT and Simon Cook, senior group leader & head of knowledge exchange & commercialisation at The Babraham Institute.
Previous winners, Reflection Therapeutics, Oppilotech and Tropo4 Therapeutics, also joined the new cohort to share their experiences of the programme.
Karolina Zapadka, head of [email protected] said: “We have really enjoyed welcoming the new cohort to the campus and I am particularly grateful to our panel for the extremely positive and stimulating discussion which kicked off our 2020/21 programme.
“Of course, given our current environment, there are challenges associated with getting everyone together, but we are fortunate to have the space available on Campus to meet in a socially distanced way.
“Bringing the cohort together, particularly during this first week was a major objective for us given that until now they hadn’t had the opportunity to meet each other face to face.
“The [email protected] programme is as much about forging the right relationships with mentors, industry experts, investors and fellow members of the cohort as it is about evolving each ventures’ scientific ideas.
“We will be working hard across the next five months to ensure that those connections continue to be made and nurtured, be that face to face on Campus or via other remote working methods.”
• PHOTOGRAPH: The third [email protected] cohort (left to right): Eugene Park, co-founder, Stroma Biosciences; Tamsin Holland-Brown, Cambridge Paediatric HealthTech; Jon Cuccui, scientific founder, ArcVax; Matthew Griffiths, CTO, ConcR.